ReviewInfection and drug resistance2016
Pelvic inflammatory disease: improving awareness, prevention, and treatment.
Review in Infection and drug resistance, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 69 citations in OpenAlex.
- Global and Regional Impact of Pelvic Inflammatory Disease in Females Across All Age Groups (1990-2021) with Projections to 2046: Findings from the 2021 Global Burden of Disease Study.International journal of women's health · 2026Article
- Nutrition in the prevention and treatment of pelvic inflammatory disease: a review.Frontiers in nutrition · 2026Review
- Article
- Article
- Article
- Innate Immune Mechanisms in Normal and Adverse Pregnancy.Advances in experimental medicine and biology · 2025Review
- Impact of patient-reported salpingitis on the outcome of hysterectomy and adnexal surgery: A national register-based cohort study in Sweden.Acta obstetricia et gynecologica Scandinavica · 2024Observational
- A randomized, double-blind, positive-controlled, Phase-II clinical trial to evaluate efficacy and safety of Fuke Qianjin capsule in Pakistani patients with pelvic inflammatory disease.Frontiers in pharmacology · 2024Article
- Risk factors for infertility and barriers to treatment in Tanzania: a survey and medical records study.African health sciences · 2023Article
- Tubal Pathologies and Fertility Outcomes: A Review.Cureus · 2023Review
- Therapeutic Efficacy of a Formulation Prepared withPharmaceutics · 2023Article
- Irisin Activates M1 Macrophage and Suppresses Th2-Type Immune Response in Rats with Pelvic Inflammatory Disease.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Identifying the clinical presentations, progression, and sequela of pelvic inflammatory disease through physiological, histological and ultrastructural evaluation of a rat animal model.Annals of translational medicine · 2021Article
- Using Innovation to Address Adolescent and Young Adult Health Disparities in Pelvic Inflammatory Disease: Design of the Technology Enhanced Community Health Precision Nursing (TECH-PN) Trial.The Journal of infectious diseases · 2021Article
- How prevalent are symptoms and risk factors of pelvic inflammatory disease in a sexually conservative population.Reproductive health · 2021Article
- Brazilian Protocol for Sexually Transmitted infections, 2020: pelvic inflammatory disease.Revista da Sociedade Brasileira de Medicina Tropical · 2021Article
- Electrokinetic Mixing for Improving the Kinetics of an HbA1c Immunoassay.Scientific reports · 2019Article
- Biological feasibility and importance of a gonorrhea vaccine for global public health.Vaccine · 2019Review
- Please Be Careful with Me: Discrepancies between Adolescent Expectations and Clinician Perspectives on the Management of Pelvic Inflammatory Disease.Journal of pediatric and adolescent gynecology · 2019Article
- Adhesive Small Bowel Obstruction due to Pelvic Inflammatory Disease: A Case Report.Saudi journal of medicine & medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
purposePelvic inflammatory disease (PID) is a common disorder of the reproductive tract that is frequently misdiagnosed and inadequately treated. PID and its complications, such as infertility, ectopic pregnancy, and chronic pelvic pain, are preventable by screening asymptomatic patients for sexually transmitted infections (STIs) and promptly treating individuals with STIs and PID. RECENT
findingsThe rates of adverse outcomes in women with PID are high and disproportionately affect young minority women. There are key opportunities for prevention including improving provider adherence with national screening guidelines for STIs and PID treatment recommendations and patient medication adherence. Nearly half of all eligible women are not screened for STIs according to national quality standards, which may increase the risk of both acute and subclinical PID. Moreover, in clinical practice, providers poorly adhere to the Centers for Disease Control and Prevention recommendations for treatment of PID. Additionally, patients with PID struggle to adhere to the current management strategies in the outpatient setting.
conclusionNovel evidence-based clinical and public health interventions to further reduce the rates of PID and to improve outcomes for affected women are warranted. We propose potential cost-effective approaches that could be employed in real-world settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.